AADvac1

Phase 2Biologic

AAxon Neuroscience SE

AADvac1 is one of 40 biologic programs targeting Progressive Supranuclear Palsy. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Progressive Supranuclear PalsyActive, not recruiting

AphasiaActive, not recruiting

Preclinical Alzheimer's DiseaseRecruiting

Progressive Supranuclear PalsyPhase 2

Active, not recruiting

AphasiaPhase 1

Active, not recruiting

Preclinical Alzheimer's DiseasePhase 2

Recruiting

Competition

Competitive Landscape

36 competitors in Progressive Supranuclear Palsy

#DrugCompanyPhaseTrials

Ambien

PPurdue Pharma LP

Approved

1 2

Belsomra

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Approved

1 3

Lithobid

SSolvay Pharmaceuticals

Approved

—4

Rilutek

AAzurity Pharmaceuticals

Exelon

2 6

Azilect

Teva

Phase 3

1 7

Aricept

Eisai

Phase 2

1 8

Depakote

AbbVie

Phase 2

1 9

Lithobid

SSolvay Pharmaceuticals

Phase 2

1 10

AMX0035

AAmylyx Pharmaceuticals Inc.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Phase 2Recruiting

Preclinical Alzheimer's Disease

NCT06957418

Q3 2029

Phase 2Not yet recruiting

Progressive Supranuclear Palsy

NCT07217665

Phase 2Not yet recruiting

Progressive Supranuclear Palsy

NCT07173803

Clinical

Trials by Indication[1]

Alzheimer's Disease3 trials

Safety Study of AADvac1, a Tau Peptide-KLH-Conjugate Active Vaccine to Treat Alzheimer's Disease

Completed·AAxon Neuroscience SE·Phase 1·NCT01850238·30 enrolled

24 Months Safety and Efficacy Study of AADvac1 in Patients With Mild Alzheimer's Disease

Completed·AAxon Neuroscience SE·Phase 2·NCT02579252·208 enrolled

18-months Safety Follow-up Study of AADvac1, an Active Tau Vaccine for Alzheimer's Disease

Completed·AAxon Neuroscience SE·Phase 1·NCT02031198·25 enrolled

Progressive Supranuclear Palsy2 trials

The Progressive Supranuclear Palsy Clinical Trial Platform - Regimen A: AADvac1

Not yet recruiting·AAdam Boxer·Phase 2·NCT07217665·146 enrolled

The Progressive Supranuclear Palsy Clinical Trial Platform

Not yet recruiting·AAdam Boxer·Phase 2·NCT07173803·440 enrolled

Preclinical Alzheimer's Disease2 trials

Alzheimer's Tau Platform (ATP): Regimen Specific Appendix for AADvac1

Enrolling by invitation·PPaul S. Aisen·Phase 2·NCT07167966·450 enrolled

The Alzheimer's Disease Tau Platform Clinical Trial

Recruiting·PPaul S. Aisen·Phase 2·NCT06957418·900 enrolled

Aphasia1 trial

A 24-month Phase 1 Pilot Study of AADvac1 in Patients With Non Fluent Primary Progressive Aphasia

Unknown status·AAxon Neuroscience SE·Phase 1·NCT03174886·33 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for AADvac1. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — AADvac1 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for AADvac1. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Axon Neuroscience SE company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: AAxon Neuroscience SE

AADvac1

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2028

Q3 2029

Trials by Indication[1]

Alzheimer's Disease3 trials

Progressive Supranuclear Palsy2 trials

Preclinical Alzheimer's Disease2 trials

Aphasia1 trial

References

Drug Info

Quick Facts

Related News